Download Project #81

Project #81
Project #81 - Spectrum Dynamics - Israel
Date: 2005/06/02
Deadline: 2006/12/31
Contact
Organisation
Spectrum Dynamics
Contact person
Dickman, Ms. Dalia
Email
[email protected]
Address
2 Haetgar Street,
Carmel Building,
P.O. Box 2026
Postcode
39120
Country
Israel
Telephone
+972-4-858-0774
Website
www.spectrum-dynamics.com
Department
Clinical Affairs
City
Tirat HaCarmel
Fax
+972-4-858-0776
Familiar with the European Framework Programme? YES
PROJECT
Title: Transrectal nuclear (molecular) imaging of primary prostate
cancer for early detection
Project type
STREP
Status
Planned for submission
Call references
Call 4th
Acronym: Prostate nuclear
imaging
Priorities’ Main Research
Areas
Life Science genomics and biotechnology for health
Workprogramme Topic
(according to each priority
workprogramme)
LSH-2005-2.2.0-9: Improving resolution of current imaging devices
relevant to cancer diagnosis and therapy
Project description
Prostate cancer is the most common non-dermatologic cancer in men in the U.S. (Kidney and Urology
Foundation of America). Definitive diagnosis of prostate cancer requires prostate biopsy and, while it is
an outpatient procedure and well tolerated, there are a number of shortcomings of the
procedure. Biopsy sensitivity is poor using the ‘sextant’ technique with repeat biopsy finding cancer in
as many as 19-28% of patients with an initially negative biopsy (Roehrborn,1996; Ellis,1995; Keetch,
1994; Fleshner, 1997). Rabbani (1998) found that 27/118 (23%) of men who underwent radical
prostatectomy had a false negative repeat transrectal ultrasound-guided sextant biopsy. The optimal
protocol for prostate biopsy is unknown.
A miniaturized trans-rectal gamma camera has been developed for imaging of prostate cancer. The
technology is based on novel photon collection and scanning geometry and includes position and
orientation tracking of the detectors as well as innovative image reconstruction algorithms. This
technology resolves the inherent trade off between resolution and sensitivity that exists in conventional
nuclear imaging and which limits its use. This technology will allow fusion of radiographic images to
nuclear-medicine imaging to yield a high sensitivity for spatial localization of prostate cancer.
In the long term the impact of this technology will improve sensitivity for cancer detection, reduce the
need for unnecessary biopsy, allow for more accurate tumor staging, and potentially allow targeted
treatment strategies. Other potential applications include targeted therapy, improved staging, and
disease monitoring after treatment or while on observation.
Keywords
Functional Molecular Imaging; Transrectal Nuclear Camera; Prostate
Cancer Diagnosis
Partners already involved
N/A
Project budget (for the
running projects)
nc
Budget reserved for
SMEs
nc
Research topics
• LSH-2005-2.2.0-9: Improving resolution of current imaging devices relevant to cancer diagnosis and
therapy - STREPs dedicated to SMEs
Profile of SME sought
Role
technology development, demonstration
Country /region
Any
Start of
partnership
start-up phase
Expertise required
Prostate cancer-specific molecular tracer development; Urologist/ Nuclear
Medicine Specialist.